Current Report Filing (8-k)
February 16 2021 - 4:50PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): February 11, 2021
ADVAXIS, INC.
|
(Exact name of registrant as specified in its charter)
|
Delaware
|
|
001-36138
|
|
02-0563870
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
305
College Road East
Princeton,
New Jersey
|
|
08540
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: (609) 452-9813
|
(Former
name or former address, if changed since last report.)
|
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
Common
stock, par value $0.001 per share
|
|
ADXS
|
|
Nasdaq
Capital Market
|
Preferred
Stock Purchase Right
|
|
-
|
|
Nasdaq
Capital Market
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act
of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company [ ]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item 5.02
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain
Officers; Compensatory Arrangements of Certain Officers.
|
On February 11, 2021, Advaxis, Inc. (the “Company”)
appointed Igor Gitelman, CPA, MBA, as the Company’s Chief Accounting Officer. In this role, Mr. Gitelman will be the Company’s
Principal Accounting Officer.
Mr. Gitelman, age 45,
has served as the Company’s VP of Finance since November 2020. Before joining the Company, Mr. Gitelman served as CFO
Executive Financial Consultant for Accu Reference Medical Labs, a clinical diagnostic laboratory. Before that, from February
2017 through November 2018, Mr. Gitelman served as a chief accounting officer of Cancer Genetics, Inc., a drug discovery, preclinical
oncology, and immuno-oncology services company. Prior to that, Mr. Gitelman served as an Assistant to Vice President (AVP)
of Finance and Tax at clinical diagnostic laboratory, BioReference Laboratories, Inc., from October 2005 to October 2016.
During this time at BioReference Laboratories, Inc., Mr. Gitelman held various positions of increasing responsibility managing
the company’s internal audit function, SEC financial reporting, tax and corporate finance functions.
There is no arrangement or understanding between Mr. Gitelman and
any other persons pursuant to which Mr. Gitelman was appointed as Chief Accounting Officer. There are no family relationships between
Mr. Gitelman and any director or executive officer of the Company, and he has no direct or indirect material interest in any transaction
required to be disclosed pursuant to Item 404(a) of Regulation S-K, nor are any such transactions currently proposed.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
February
16, 2021
|
ADVAXIS,
INC.
|
|
|
|
By:
|
/s/
Kenneth A. Berlin
|
|
Name:
|
Kenneth
A. Berlin
|
|
Title:
|
Chief
Executive Officer
|
Ayala Pharmaceuticals (QX) (USOTC:ADXS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ayala Pharmaceuticals (QX) (USOTC:ADXS)
Historical Stock Chart
From Apr 2023 to Apr 2024